INS and diabetes mellitus: Furthermore, patients with diabetes were likely to receive non-recommended 60 mg dose regardless of insulin treatment (DM on insulin: 10.9%; DM not on insulin: 8.7%; no DM: 5.0%; Fig. 3C).